Anúncio
Anúncio

IMDX

I

Insight Molecular Diagnostics Inc. Common Stock

7.45
USD
Patrocinado
-0.05
-0.73%
09 de jan., 15:58 UTC -5
Encerrado
exchange

Pós-Mercado

7.45

0.00
0.00%

Relatórios de Lucros IMDX

Rácio de surpresa positiva

IMDX separação 15 de 40 últimas estimativas.

38%

Próximo Relatório

Data do Próximo Relatório
23 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$295.80K
/
-$0.24
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+13.77%
/
-29.41%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-80.09%
/
-87.56%

Insight Molecular Diagnostics Inc. Common Stock earnings per share and revenue

On 10 de nov. de 2025, IMDX reported earnings of -0.34 USD per share (EPS) for Q3 25, missing the estimate of -0.21 USD, resulting in a -58.95% surprise. Revenue reached 260.00 mil, compared to an expected 289.68 mil, with a -10.25% difference. The market reacted with a +10.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -0.24 USD, with revenue projected to reach 295.80 mil USD, implying an diminuir of -29.41% EPS, and aumentar of 13.77% in Revenue from the last quarter.
FAQ
For Q3 2025, Insight Molecular Diagnostics Inc. Common Stock reported EPS of -$0.34, missing estimates by -58.95%, and revenue of $260.00K, -10.25% below expectations.
The stock price moved up 10.66%, changed from $6.80 before the earnings release to $7.53 the day after.
The next earning report is scheduled for 23 de mar. de 2026.
Based on 6 analistas, Insight Molecular Diagnostics Inc. Common Stock is expected to report EPS of -$0.24 and revenue of $295.80K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio